Restricted accessCase reportFirst published online 2010-06
Rituximab Treatment for Thrombotic Thrombocytopenic Purpura Associated with Human Immunodeficiency Virus Failing Extensive Treatment with Plasma Exchange: A Report of Two Cases
In an urban area with a 3% prevalence of HIV infection, two women presented in a 1-year period with AIDS and thrombotic thrombocytopenic purpura (TTP). TTP was diagnosed in each patient based on the presence of thrombocytopenia, schistocytes, and markedly elevated lactate dehydrogenase (LDH) activity. Initial treatment with plasma exchange resulted in resolution of these abnormalities. However, the discontinuation of plasma exchange resulted in the prompt recurrence of laboratory abnormalities diagnostic for TTP. Treatment failure was established after observing 6 and 4 such responses requiring 41 and 40 episodes of plasma exchange for each patient, respectively. Patients were subsequently treated with 2–4 doses of weekly rituximab resulting in durable remission. These patients are now 21 and 9 months beyond rituximab treatment. Rituximab appears to be safe and effective in this setting.
Get full access to this article
View all access options for this article.
References
1.
GeorgeJN. Thrombotic thrombocytopenic purpura. N Engl J Med, 2006; 354:1927–1935.
2.
FurlanM, RoblesR, GalbuseraMet al.Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med, 1998; 339:1578–1584.
3.
BejaminM, TerrellDR, VeselySKet al.Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis, 2009; 48:1129–1137.
4.
MooreRD. Schistocytosis and a thrombotic microangiopathy-like syndrome in hospitalized HIV-infected patients. Am J Hematol, 1999; 60:116–120.
5.
StefanescueR, BassettD, ModarresiR, SantiagoF, FakruddinM, LaurenceJ. Synergistic interactions between interferon-γ and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis. Blood, 2008; 112:340–349.
6.
LaurenceJ, MitraD, SteinerM, Staiano-CoicoL, JaffeE. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood, 1996; 87:3245–3254.
7.
Maryland Department of Health and Mental Hygiene. Baltimore City HIV/AIDS Epidemiological Profile. Fourth Quarter, 2008. www.dhmh.state.md.us/AIDS/Data&Statistics/BaltimoreCityHIVEpiProfile122008.pdf. 2009 January 19.
8.
GervasonC, RidolfoAL, VaccarezzaMet al.Thrombotic Microangiopathy in Patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis, 2002; 35:1534–1540.
9.
TerrellDR, WilliamsLA, VeselySK, LammleB, HovingaJAK, GeorgeJN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost, 2005; 3:1432–1436.
10.
NovitzkyN, ThomasJ, AbrahamsL, du ToitC, McDonaldA. Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br J Hematol, 2005; 128:373–379.
11.
KaplanLD, LeeJY, AmbinderRFet al.Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 2005; 106:1538–1543.
12.
BowerM, VeraitchO, SzydloRet al.Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood, 2009; 113:4521–4524.
CoppoP, AdrieC, AzoulayEet al.Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit (ICU) patients?Intens Care Med, 2003; 29:564–569.
